Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study

Abstract

Background: The study aimed at assessing the prevalence and clinical profile of minimal hepatic encephalopathy (MHE) in patients with cirrhosis using neuropsychological assessment and at understanding the management practices of MHE in the Indian clinical setting. Methods: This cross-sectional, clinicoepidemiological study conducted at 20 sites enrolled liver cirrhosis patients with Grade 0 hepatic encephalopathy according to West-Haven Criteria. Patients were subjected to mini-mental state examination and those with a score of $24 were assessed using psychometric hepatic encephalopathy score. Short Form-36 questionnaire was administered to assess the impact on health-related quality of life. Results: Of the 1260 enrolled patients, 1114 were included in the analysis. The mean age was 49.5 years and majority were males (901 [81%]). The prevalence of MHE was found to be 59.7% (665/1114) based on the psychometric hepatic encephalopathy score of #À5. Alcohol-related liver disease was the most common etiology (482 [43.27%]) followed by viral infection (239 [21.45%]). Past smokers as well as those currently smoking were more likely to have MHE than nonsmokers. A significant association was found between tobacco chewing, smoking, alcohol consumption, diabetes, and the presence of MHE. Multivariable analysis revealed smoking as the only parameter associated with MHE. A total of 300 (26.9%) patients were on prophylaxis with lactulose/lactitol or rifaximin. These patients were less likely to have MHE as compared to those not on prophylaxis (odds ratio, 0.67; 95% confidence interval, 0.50-0.88; P = 0.005). Conclusion: The disease burden of MHE is quite substantial in patients with cirrhosis with no apparent cognitive defect. Smoking, whether past or current, has significant association with the presence of MHE. Although MHE has been shown to adversely affect quality of life, prophylaxis for MHE is not routinely practiced in the Indian setting. The study has been registered under clinical trials registry of India (CTRI/2014/01/004306). (J CLIN EXP HEP

Efficacy of Zinc Supplement in Minimal hepatic Encephalopathy: A prospective, Randomized Controlled Study (Zinc-MHE Trial)

“…A diagnosis of MHE has often been overlooked by real world practice. MHE is a condition which has a significant -Garza et al, 2011;Rathi et al, 2019;Elgohary et al, 2020;Das et al, 2001). In our study, the prevalence of MHE was 55% in compensated cirrhotic patients.…”

EncephalApp Stroop Test for covert hepatic encephalopathy screening in Tunisian cirrhotic patients

“…21,25 Smoking was also considered as a risk factor for MHE. 41,42 In our study, CHE was more frequent in women, elderly patients and in patients whose level of school education is between 6 and 13 years compared to patients with education level <6 years and >13 years). None of our patients had alcoholic cirrhosis.…”

Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor β1

“…47e50 Clinical treatments for HE that commonly are used are lactulose and rifaximin, which reduce ammonia levels and have been shown to improve outcomes. 51,52 That being said, these treatments have differing degrees of therapeutic efficacy depending on the metric assessed. Therefore, the need to develop new therapies, or therapies to use in conjunction with current treatments, for management of this syndrome is critically important.…”